Revision history of "New epigenetic inhibitors for the treatment of chronic diseases" (Q3216126)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

9 October 2024

  • curprev 00:3200:32, 9 October 2024DG Regio talk contribs 67,480 bytes 0 Changed label, description and/or aliases in pt
  • curprev 00:3200:32, 9 October 2024DG Regio talk contribs 67,480 bytes +64 Set a claim value: summary (P836): O principal objetivo da Oryzon é tornar-se líder global no desenvolvimento de inibidores epigenéticos para desenvolver terapias em doenças com forte necessidade médica não satisfeita. Embora a Oryzon seja agora um líder mundial para a meta LSD1 em cancro e doenças neurodegenerativas, para que a empresa seja considerada um líder global neste campo, deve alargar ou fazer avanços nos seus programas de investigação sobre outros alvos além do LSD1 ou exp...

22 March 2024

12 June 2023

22 February 2023

18 August 2022

  • curprev 13:4513:45, 18 August 2022DG Regio talk contribs 65,679 bytes +44,925 Changed label, description and/or aliases in el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl, nl, fr, de, it, es, and other parts: Adding translations: el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl,

16 January 2022

17 December 2021

10 December 2021

5 December 2021

21 October 2021

12 October 2021

11 October 2021

10 October 2021

9 October 2021